NO952077L - Sammensetning bestående av en dendrimer og en aktiv substans okkludert deri - Google Patents

Sammensetning bestående av en dendrimer og en aktiv substans okkludert deri

Info

Publication number
NO952077L
NO952077L NO952077A NO952077A NO952077L NO 952077 L NO952077 L NO 952077L NO 952077 A NO952077 A NO 952077A NO 952077 A NO952077 A NO 952077A NO 952077 L NO952077 L NO 952077L
Authority
NO
Norway
Prior art keywords
dendrimer
active substance
composition consisting
composition
occluded
Prior art date
Application number
NO952077A
Other languages
English (en)
Other versions
NO952077D0 (no
Inventor
Johan Franz Gradus Anto Jansen
Egbert Willem Mijer
Ellen Marleen Monique De Berg
Original Assignee
Dsm Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL9400880A external-priority patent/NL9400880A/nl
Application filed by Dsm Nv filed Critical Dsm Nv
Publication of NO952077D0 publication Critical patent/NO952077D0/no
Publication of NO952077L publication Critical patent/NO952077L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/16—Dendrimers and dendritic polymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en sammensetning bestående av en dendrimer utstyrt med blokkerende midler og en aktiv substans okkludert i dendrimeren. Et blokkerende middel er en forbindelse som sterisk er av tilstrekkelig størrelse, som lett entrer inn i en kjemisk binding med. en dendrimers terminale gruppe, og som også kan avspaltes fra dendrimeren eller modifiseres uten derved å påvirke dendrimer- ens kjemiske struktur og den aktive substans. Det blokkerende middel kan være forsynt med beskyttende grupper. Slike konjugater har den fordel at tidspunktet for starten av frigivelsen av den aktive substans kan, reguleres. Det beskrives også den fremgangsmåte for fremstil- ling av en slik sammensetning og en fremgangsmåte for kontrollert frigivelse av den aktive substans.
NO952077A 1994-05-27 1995-05-26 Sammensetning bestående av en dendrimer og en aktiv substans okkludert deri NO952077L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9400880A NL9400880A (nl) 1994-05-27 1994-05-27 Samenstelling bestaande uit een dendrimeer en een in het dendrimeer opgesloten actieve stof, een werkwijze voor de bereiding van een dergelijke samenstelling en een werkwijze voor het vrijstellen van de actieve stof.
NL9401886A NL9401886A (nl) 1994-05-27 1994-11-11 Samenstelling bestaande uit een dendrimeer en een in het dendrimeer opgesloten actieve stof, een werkwijze voor de bereiding van een dergelijke samenstelling en een werkwijze voor het vrijgeven van de actieve stof.

Publications (2)

Publication Number Publication Date
NO952077D0 NO952077D0 (no) 1995-05-26
NO952077L true NO952077L (no) 1995-11-28

Family

ID=26647222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952077A NO952077L (no) 1994-05-27 1995-05-26 Sammensetning bestående av en dendrimer og en aktiv substans okkludert deri

Country Status (17)

Country Link
US (1) US5788989A (no)
EP (1) EP0684044A3 (no)
JP (1) JPH07330631A (no)
KR (1) KR950031112A (no)
CN (1) CN1117875A (no)
AU (1) AU2034395A (no)
BR (1) BR9502555A (no)
CA (1) CA2150204A1 (no)
CZ (1) CZ137295A3 (no)
FI (1) FI952573A (no)
HU (1) HU216621B (no)
NL (1) NL9401886A (no)
NO (1) NO952077L (no)
NZ (1) NZ272208A (no)
PL (1) PL308785A1 (no)
RU (1) RU95108318A (no)
SK (1) SK70395A3 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658574A (en) * 1995-10-13 1997-08-19 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cleansing compositions with dendrimers as mildness agents
NL1001753C2 (nl) * 1995-11-28 1997-05-30 Dsm Nv Samenstelling omvattende een kunststof en een additief.
GB9525773D0 (en) * 1995-12-16 1996-02-14 Unilever Plc Detergent composition
DE19625982A1 (de) * 1996-06-28 1998-01-02 Wella Ag Kosmetisches Mittel zur Haarbehandlung mit Dendrimeren
WO1998006691A2 (en) 1996-08-14 1998-02-19 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
DE19726340C2 (de) * 1996-08-16 1999-05-06 Schering Ag Zinndendrimere, ihre Verwendung als Röntgenkontrastmittel und Verfahren zu ihrer Herstellung
US20010011109A1 (en) * 1997-09-05 2001-08-02 Donald A. Tomalia Nanocomposites of dendritic polymers
AU6239998A (en) * 1997-01-13 1998-08-03 Dendritech Inc. Nanocomposites of dendritic polymers
FR2759582A1 (fr) * 1997-02-14 1998-08-21 Oreal Composition deodorante
FR2761691B1 (fr) 1997-04-03 1999-05-14 Oreal Polymeres a fonction terminale thiol
FR2761601A1 (fr) 1997-04-04 1998-10-09 Oreal Compositions cosmetiques autobronzantes
EP0875521A1 (en) * 1997-04-30 1998-11-04 Unilever Plc A detergent composition
FR2763505B1 (fr) * 1997-05-22 2000-10-06 Oreal Utilisation en cosmetique de certains polymeres polyamines comme agents anti-oxydants
FR2763852B1 (fr) 1997-05-28 1999-07-09 Oreal Composition comprenant un derive de l'acide cinnamique et un polymere polyamine
FR2763851B1 (fr) 1997-05-28 1999-07-09 Oreal Compositions comprenant un derive de dibenzoylmethane et un polymere polyamine
GB9711625D0 (en) * 1997-06-06 1997-07-30 Ciba Geigy Ag Pigment compositions
US20040072937A1 (en) 2001-02-10 2004-04-15 Tomalia Donald A. Nanocomposites of dendritic polymers
FR2772771B1 (fr) * 1997-12-19 2000-01-28 Oreal Utilisation de polymeres hyperbranches et de dendrimeres comportant un groupement particulier, en tant qu'agent filmogene, les compositions filmogenes les comprenant et leur utilisation notamment en cosmetique ou en pharmacie
FR2772770B1 (fr) * 1997-12-19 2000-01-28 Oreal Nouveaux composes choisis parmi les polymeres hyperbranches et les dendrimeres ayant un groupement particulier, procede de preparation, utilisation et compositions les comprenant
US6475994B2 (en) * 1998-01-07 2002-11-05 Donald A. Tomalia Method and articles for transfection of genetic material
DE19936997B4 (de) * 1999-08-02 2007-06-14 Biolitec Ag Verfahren zur Applikation von Photosensibilisatoren (PS) mittels Multiplikatoren in der photodymamischen Therapie
FI19991705A (fi) * 1999-08-11 2001-02-12 Neste Chemicals Oy Antimikrobinen hyperhaaroittunut polymeerikoostumus
US6261794B1 (en) * 1999-10-14 2001-07-17 Saint Louis University Methods for identifying inhibitors of methionine aminopeptidases
US20070031473A1 (en) * 2005-08-05 2007-02-08 Peyman Gholam A Drug delivery system and method
WO2002033732A2 (en) * 2000-10-14 2002-04-25 Triton Systems, Inc. Sensors comprising a semi-conductive polymer
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US6780428B2 (en) 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
US20020182701A1 (en) * 2001-08-30 2002-12-05 Saint Louis University Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
US20030180250A1 (en) * 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
FR2840622B1 (fr) * 2002-06-11 2004-07-23 Rhodia Chimie Sa Composition pour le traitement des articles en fibres textiles comprenant un polymere dendritique
US20050271615A1 (en) * 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060387A1 (en) 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7153905B2 (en) * 2003-03-21 2006-12-26 The General Hospital Corporation Hyperbranched dendron and methods of synthesis and use thereof
US7048864B2 (en) * 2003-03-24 2006-05-23 King Technology Inc. Dendrimer fluid purification system and method
US7361715B2 (en) * 2003-12-16 2008-04-22 Ppg Industries Ohio, Inc. Polymer additives for powder coatings
US20060269480A1 (en) * 2005-05-31 2006-11-30 Ramot At Tel Aviv University Ltd. Multi-triggered self-immolative dendritic compounds
US8114393B2 (en) * 2005-09-14 2012-02-14 Wisconsin Alumni Research Foundation Methods and compositions for phosphate binding
US8158117B2 (en) * 2005-09-14 2012-04-17 Wisconsin Alumni Research Foundation Methods and compositions for phosphate binding
CN101003607B (zh) * 2006-01-16 2010-09-01 博阳生物科技（上海）有限公司 封闭树状大分子的方法、经封闭的树状大分子及其用途
JP2010504318A (ja) * 2006-09-22 2010-02-12 ラボファーム インコーポレイテッド ｐＨ標的化薬剤送達のための組成物及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694064A (en) * 1986-02-28 1987-09-15 The Dow Chemical Company Rod-shaped dendrimer
US5338532A (en) * 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
ES2054678T5 (es) * 1986-08-18 1997-09-16 Dow Chemical Co Conjugados estrella.
US5530092A (en) * 1992-01-13 1996-06-25 Dsm N.V. Dendritic macromolecule and the preparation thereof

Also Published As

Publication number Publication date
EP0684044A2 (en) 1995-11-29
RU95108318A (ru) 1997-03-20
NO952077D0 (no) 1995-05-26
HU216621B (hu) 1999-07-28
CZ137295A3 (en) 1995-12-13
AU2034395A (en) 1995-12-07
KR950031112A (ko) 1995-12-18
FI952573A (fi) 1995-11-28
NZ272208A (en) 1996-07-26
CA2150204A1 (en) 1995-11-28
HU9501554D0 (en) 1995-07-28
JPH07330631A (ja) 1995-12-19
SK70395A3 (en) 1996-05-08
BR9502555A (pt) 1996-04-30
PL308785A1 (en) 1995-12-11
CN1117875A (zh) 1996-03-06
EP0684044A3 (en) 1996-03-06
NL9401886A (nl) 1996-01-02
FI952573A0 (fi) 1995-05-26
HUT71258A (en) 1995-11-28
US5788989A (en) 1998-08-04

Similar Documents

Publication Publication Date Title
NO952077L (no) Sammensetning bestående av en dendrimer og en aktiv substans okkludert deri
NO20002605D0 (no) Speroider, fremstillingsmetode og farmasøytiske sammensetninger
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
ATE255589T1 (de) Kristallin form i von clarithromycin
WO1998022136A3 (de) Stabile lyophilisierte pharmazeutische zubereitungen von mono- oder polyklonalen antikörpern
PL328858A1 (en) Immunogenous peptides
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
TR200102977T2 (tr) Yeni tedavi yöntemi.
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
DE69906938D1 (de) Glococorticoid selektive entzündungshemmende mittel
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
NO20005668D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
EP0932613A4 (en) EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS
DK1032391T3 (da) Sfæroider indeholdende tiagabin, fremstillingsproces og farmaceutisk sammensætning
DK1207870T3 (da) Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
DE60040616D1 (de) Verfahren zur behandlung maligner zellen eines patienten und pharmazeutische zusammensetzung zu dessen anwendung
EP1192952A3 (en) Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
DK0821588T3 (da) Levobupivacain og anvendelse heraf som et anæstetikum til gravide kvinder
DE3878154D1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
KR970061245A (ko) 프로제스테론 및 에스트로젠 작동약을 사용한, 뼈 손실 예방용 약학 조성물
ATE232724T1 (de) Inhibitor von stickstoffmonoxid (no) synthase zur verhütung von typ ii diabetes
Calinski Terminology 1990
Maria The ILO's International Standards; What They Meal for Nurses
ZA968019B (en) Novel composition containing an acid labile benzimidazole and process for its preparation.